GenScript and Bioelectronica Announce Strategic Collaboration to Accelerate Antibody Discovery

Combining single B-cell precision with global development power — trusted by 200,000+ scientists worldwide

August 30, 2025

Piscataway, NJ, August 30 – GenScript Biotech Corporation (“GenScript”) today announced a strategic collaboration with Bioelectronica Holdings Inc. (“Bioelectronica”), marking another milestone in its growing global network of innovation partners. The partnership combines Bioelectronica’s industry-leading single B-cell high-throughput screening technology with GenScript’s end-to-end gene and antibody development & expression platforms, delivering integrated solutions that help pharma and biotech accelerate therapeutic antibody discovery with confidence.

Technology Synergy: Single B-Cell Discovery Powered by TurboCHO™ Expression

At the core of this collaboration lies Bioelectronica’s HyperCell™ high-throughput single-cell screening system, powered by its proprietary AI-driven antibody prediction software AbFinder™. This advanced platform enables precise identification of high-quality antibody sequences at unprecedented speed and accuracy.

GenScript complements this with its industry-leading capabilities in gene synthesis, protein expression, and antibody engineering. In particular, GenScript’s TurboCHO™ transient expression platform enables clients moving from HyperCell screening to antibody validation to obtain purified antibodies in as little as 5 business days — ensuring a seamless sequence-to-data workflow trusted by the world’s top pharma and biotech innovators.

Collaborative Value Highlights

• 50% faster clone verification vs. traditional methods
• Significant cost savings through automated workflows and economies of scale
• Global accessibility via GenScript’s 15+ international sites
• Exclusive customer benefit: For users advancing from HyperCell discovery into GenScript expression orders, Bioelectronica will provide special subsidies to ensure highly competitive pricing

Executive Perspectives

Jianjun Sun, CEO of Bioelectronica, commented:
"Bioelectronica’s collaboration with GenScript marks a significant step in expanding the applications of single B-cell technology. Leveraging GenScript’s extensive expertise in antibody services and its global network, this partnership provides an ideal platform for the commercialization of single B-cell technology, helping users reduce costs and accelerating the adoption of our solutions by customers worldwide."

Ray Chen, President of GenScript Life Science Group, added:
“This collaboration aligns with our commitment of scripting possibilities in Antibody Discovery. By integrating Bioelectronica’s precision screening capabilities with our TurboCHO™ expression platform and global outreach infrastructure, we will provide Antibody Discovery researchers with a streamlined solution to shorten R&D cycles by up to 50%, surpassing the current capabilities of any single-platform provider."

Five-Year Roadmap

Over the next five years, GenScript and Bioelectronica will jointly develop:

• Simpler workflows — standardized single B-cell screening, faster and easier to adopt.
• Smarter discovery — AI-driven prediction for higher-quality antibody candidates.
• Seamless scale-up — global access to GenScript’s sites for smooth transition from discovery to validation.
• Faster results — integrated with TurboCHO™, delivering antibodies in just days.

About GenScript Biotech Corporation

Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners—from academic institutions to industry leaders—to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 5,500+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world’s Top 20 pharma companies.

Learn more at www.genscript.com

About Bioelectronica

Founded in 2016 in Reno, Nevada, Bioelectronica offers Hypercell Platform and AbFinderAI Software solution to accelerate antibody discovery, by leveraging the power of single cell secretion sorting with the next-generation sequencing (NGS) guided hits list selection.